TB-500 dosage and half-life: the larger amount failed
The rat stroke experiment gives “more” an awkward ending. Its study amounts do not establish a human TB-500 regimen.
The highest rat dose did not win
In the male Wistar rat embolic-stroke dose-response study, researchers gave full-length thymosin beta-4 intraperitoneally at 2, 12 and 18 mg/kg. Treatment began 24 hours after stroke. Neurological function improved at 2 and 12 mg/kg, with significant findings from day 14 through day 56; 18 mg/kg gave no significant benefit. A modeled optimal dose of about 3.75 mg/kg was proposed.
I expected the highest amount to be the strongest argument for the protein. It was not. The response was non-monotonic: the benefit did not simply rise with dose. The modeled optimum was a calculation within that animal experiment; a human amount remains unestablished by a clinical trial.
Community “loading then maintenance” plans have no validation in controlled human TB-500 trials. Nothing in the rat finding supplies that validation. These regimens describe what experimental subjects received. They provide no instructions for human use.
Forty healthy volunteers received a different molecule
The 2010 randomized, placebo-controlled Phase 1 study gave full-length synthetic thymosin beta-4 intravenously to 40 healthy volunteers in four cohorts of 10. The studied amounts were 42, 140, 420 or 1260 mg. The study examined single and multiple doses over 14 days.
The study reported infrequent mild or moderate adverse events, no dose-limiting toxicities and no serious adverse events. Blood exposure was dose-proportional, and half-life increased with dose. Those are encouraging early tolerability findings for the full protein, under those study conditions; they do not establish a safe TB-500 dose or long-term safety.
My concern with quoting only “well tolerated” is what disappears around it: the whole molecule, the healthy participants and the limited observation period. The finding becomes much larger when those conditions are cut away.
The TB-500 half-life number is still absent
No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide in this research record. A half-life is the time needed for the amount of a substance to fall by half. The intravenous parent-protein study and TB-500 detection in horse plasma and urine answer other questions; neither establishes a human half-life for the fragment.
The routes also apply to their specific experiments. Rat studies often used intraperitoneal administration, the human Phase 1 study used intravenous thymosin beta-4, and wound research used topical full-length protein. Those differences cannot be turned into a choice of human TB-500 route.
I would trust a measured human fragment result more than a confident number circulating without one. The reading list contains the actual pharmacokinetic paper, and the FDA record documents the fragment’s missing human exposure data.